Modulatory Effects of Gingerol in Cancer Cell Growth Through Activation and Suppression of Signal Pathways in Cancer Cell Growth Systemic Review Authors: J Juvaid Noor, R. Sindhu, A Banu Jothi, D Prabu, M Raj Mohan, Dinesh Dhamodhar, Lubna Fathima, R Haripriya Published: 2024 ABSTRACT ABSTRACTBackground:Gingerol is a traditional medicinal herb used to treat various cancers. The current review aims to explore the modulatory effects of gingerol on cancer cell growth through the activation and suppression of key signaling pathways involved in cancer progression.Methods:A literature search was conducted on the databases such as PubMed, Cochrane, Google Scholar, and Embase. The inclusion criteria for the study were randomized control trials conducted during 2011–2023. Seven articles were selected for inclusion in the systematic review.Results:There was clinically significant evidence due to intervention in changes of nausea-related quality of life (QoL), overall chemotherapy-induced nausea and vomiting-related QoL, delayed nausea severity, fatigue, low incidence of malnutrition, and a high compliance rate. The findings of the study suggest that 6-gingerol hinders cell viability and induces cell death in prostate cancer cells, which is dependent on time and dose. 6-Gingerol could be developed as a complementary therapy to cisplatin in the management of ovarian cancer, offering a strategy to enhance therapeutic outcomes and minimize toxicity.Conclusions:This systematic review highlights the potential of ginger in malignancy treatment due to its ability to activate and suppress various signaling pathways. The review underscores the need for further in-depth studies and more clinical trials in humans to better understand the precise mechanisms and to validate the efficacy of ginger. INTRODUCTION Cancer is an intricate disease characterized by uncontrolled cell growth and proliferation, leading to tumor formation and metastasis. Traditional treatments such as chemotherapy and radiation have significant side effects, driving the search for more targeted and less toxic therapies. Natural compounds, such as gingerol from ginger (Zingiber officinale), have shown promise in cancer therapy. Gingerol modulates key cellular pathways involved in carcinogenesis, influencing cell proliferation, apoptosis, angiogenesis, and metastasis. It activates pro-apoptotic pathways and suppresses pro-survival signaling, inducing apoptosis by increasing Bax expression and decreasing Bcl-2, resulting in mitochondrial dysfunction and caspase activation.[1] In addition, gingerol inhibits the NF-κB signaling pathway, which is often constitutively active in many cancers and is associated with inflammation, cell survival, and metastasis[2] Gingerol might play a crucial role in Cancer progression. Gingerol has been shown to influence the tumor microenvironment by modulating inflammatory cytokines and immune cell activity. For instance, gingerol reduces the levels of pro-inflammatory cytokines such as TNF-α and IL-6, which are often elevated in the tumor microenvironment and contribute to cancer progression.[13] By mitigating inflammation, gingerol helps in creating a less conducive environment for tumor growth and metastasis. Gingerol exerts its effects through the modulation of key signaling pathways, including the PI3K/Akt and MAPK/ERK pathways. These pathways play pivotal roles in regulating cell growth, survival, and apoptosis. By inhibiting the activation of Akt and affecting MAPK/ERK signaling, gingerol may reduce cell proliferation and induce cell cycle arrest.[4] Gingerol’s effects extend beyond intracellular signaling pathways to include interactions with the extracellular matrix (ECM). The ECM provides structural support to tissues and is involved in various cellular processes, including metastasis. Gingerol has been found to alter ECM composition and inhibit the expression of ECM-degrading enzymes, such as MMPs, thereby reducing tumor invasion and metastasis.[5] By stabilizing the ECM, gingerol may prevent cancer cells from breaking through tissue barriers and spreading to distant sites. Moreover, gingerol’s impact on the MAPK/ERK pathway enhances its anticancer properties. Inhibiting this pathway leads to reduced cell growth and leads to restriction of the cell cycle at the G2/M phase.[6] The current study focused on offering an in-depth review of the modulatory sequelae of gingerol on the development of cancer cells through the activation and suppression of key signaling pathways. The study aims to highlight gingerol’s potential as a novel therapeutic agent in the treatment of different tumors by clarifying the molecular mechanisms behind its anticancer actions. MATERIALS AND METHODS This systematic review was conducted for the effectiveness of gingerol in cancer cell growth through activation and suppression of signal pathways in cancer cell growth. This Systematic review was conducted following PRISMA Guidelines.[7] Eligibility criteria The inclusion criteria for the study were randomized control trials conducted during 2011–2023, studies specifically exploring the impact of gingerol on cancer prevention, and full-length articles compiled in a single language (English). The exclusion criteria for the study were studies that did not specifically use cancer cell lines or focused on noncancer-related pathways and published in languages other than English if language limitations apply. Search strategy Articles were collected from databases such as PubMed, Cochrane, Google Scholar, and Embase. Search term used for identification of the studies were “Gingerol” AND “Cancer cell growth”; “Gingerol” AND “apoptosis”; “Gingerol” OR “ Zingiber Officinale” AND “apoptosis”. RESULTS This research resulted in 16 articles, of which 10 were full-text articles having accessibility and were eligible for review. Ultimately, seven articles were chosen for inclusion in this systematic review [Figure 1]. PRISMA 2020 flow diagram for newly conducted systematic reviews that solely involved database and registration searches[7] Table 1 shows the Characteristics of the studys included in the systematic review with Author name, samples recruited, sample characteristics, duration of the study and sample allocation. Table 1Features of the study’s interventionsAuthor nameSample sizePatient characteristicsDurationPatient allocationKim HW et al., 2011[8]human prostate cancer cells (LNCaP)LNCaP human prostate cancer cells from in vitro investigations, not actual patients.24 and 48 hThree distinct forms of 6-gingerol were incubated with a 1 mL aliquot of the aggressively proliferating LNCaP cells, which contain 1×105 cells per mL, applied to each of the 24 well plates.J. Konmun et al., 2017[9]88Patient eligible criteria were≥18 years old and newly diagnosed with histology of solid tumors with Eastern Cooperative Oncology Group (ECOG) performance status ≤2.64 days6-gingerol (n=42) Placebo (n=46)Wolfgang. Marx et al., 2018[10]300Patient with no prior history of chemotherapy, ≥18 years old, baseline Karnofsky score >60.5 monthsParticipants were randomized into intervention and placebo groups (1:1).Chi-Ming Liu et al., 2022[11]96-well platesThe human prostate cancer LNCaP, DU145, and PC3 cell lines24, 48, and 72 hLNCaP, DU145, and PC3 cells were seeded at a thickness of 1×104 cells per well in 96-well plates.Megan Crichton et al., 2024[12]103Chemotherapy (-ve) adults, Scheduled, physically and cognitively functional.2 years 2 monthsParticipants were divided into two groups at random: the ginger group (n=52) and the placebo group (n=51).Zohreh Salari et al., 2023[13]300OVCAR-3 cells (ovarian cancer cells) and two human umbilical vein endothelial cell (HUVEC) cell lines were used as a control group.24, 28, and 72 hStudy group- 6-gingerol Positive control -sterile distilled waterBaptista Moreno Martin AC et al. 2020[14]4T1Br4 murine TNBC cellsSyngeneic and xenograft orthotopic models.24 and 72 h4T1Br4 and HMTL MDA-MB-231.Six replicate wells of 96-well plates were seeded with six cells each in complete media (1×103/100 µL/well and 2×103/100 µL/well, respectively). Features of the study’s interventions Table 2 Shows the intervention used in the study included with the outcome. Table 2Features of the findings from the research that were part of the systematic reviewAuthor nameType of studyInterventionResultKim HW et al., 2011[8]In vitro studyThe cells were treated with varying concentrations of 6-gingerol (100, 200, and 300 µM)There was a statistically significant difference between 24 and 48 hours in 300 µM dosage (P<0.05)J. Konmun et al., 2017[9]Randomized double-blind placebo-controlled study42 patients received 6-gingerol 10 mg 46 patients received a placebo of diluents/binder and thixitripic thickening.Between the groups in CR, there were statistically significant differences (P<0.001), means of appetite (P=0.001), FACT-G score (P<0.001)Wolfgang Marx et al., 2018[10]“SPICE trial (Protocol for a multicenter double-bind placebo-controlled randomized trial)”Study group: 60 mg of active gingerols per day. Placebo: placebo capsulesIncomplete outcome data on gingerolChi-Ming Liu et al., 2022[11]In vitro study6-gingerol (95 99% purity, verified by high-performance liquid chromatography) was applied to the cells.6-gingerol reduced the viability of prostate cancer by controlling ferroptosis and autophagy. Furthermore, there was an inhibition of cell migration, adhesion, and invasion (P=0.05).Megan Crichton et al., 2024[12]parallel, double-blind, placebo-controlled randomized trialBeginning on the day of chemotherapy and continuing for five days, either a placebo or four standardized ginger capsules (a total of 84 mg/day of active gingerols) were administered.There was clinically significant evidence due to intervention in changes of nausea-related QoL (P=0.003), overall CINV-related QoL (P<0.001), delayed nausea severity (P=0.003), fatigue (P=0.002), low incidence of malnutrition (P=0.032)Zohreh Salari et al., 2023[13]In silico, in vitro and in vivo studyHUVEC cell lines (5×104) were extracted and stored for a full day to conduct an in vitro, in vitro, and silico study. Fresh media was added to each well of the plate, along with 10 mL of various concentrations of 6-gingerol, cisplatin, and a combination of both. Analysis of Gene Expression. And Histopathological Assessment: Quantitative PCR (qPCR)There were statistically high significant differences in the experimental group for the proportion of apoptosis (P<0.001)Baptista Moreno Martin AC et al. 2020[13]In vitro study[10]-gingerol or doxorubicin alone or in combinations for 24 hThe combination of doxorubicin and [10]-gingerol significantly increased the number of apoptotic cells, compared to each compound alone (P<0.01) Features of the findings from the research that were part of the systematic review Table 3 shows the risk of bias in all the included studies based on the Office of Health Assessment and Translation assessment tool.[1516] Table 3Quality assessment of all the included studies[16]Author nameRandomizationAllocation ConcealmentComparison groupConfoundingExperimental conditionsBlindingComplete outcome dataExposure CharacterizationOutcome AssessmentOutcome ReportingNo other threatsKim HW et al., 2011[8]J. Konmun et al., 2017[9]Wolfgang. Marx et al., 2018[10]Chi-Ming Liu et al., 2022[11]Megan Crichton et al., 2024[12]Zohreh Salari et al., 2023[13]Baptista Moreno Martin AC et al. 2020[14] Definitely low risk of bias Probably low risk of bias Probably high risk of bias Definitely high risk of bias Quality assessment of all the included studies[16] Definitely low risk of bias Probably low risk of bias Probably high risk of bias Definitely high risk of bias DISCUSSION Gingerol, a bioactive component of ginger, inhibits many signaling pathways to drastically reduce the development of cancer cells. It activates tumor suppressor pathways, inhibiting cancer cell proliferation and inducing apoptosis, while also suppressing oncogenic pathways to reduce proteins and enzymes that promote cancer cell survival and metastasis. This dual action suggests gingerol’s potential for cancer prevention and therapy, emphasizing the role of natural compounds in combating cancer. Kim HW et al. (2011)[8] conducted an in vitro trial on prostate cancer, a prevalent malignancy and major cause of cancer deaths in men. The aging population is expected to increase prostate cancer incidence. Chemoprevention with natural dietary substances, or phytochemicals, is seen as a promising approach. Prostate cancer has a lengthy latency period, which makes chemopreventive medication an option for intervention. The study focused on 6-gingerol, a phytochemical in ginger known for its anti-inflammatory, analgesic, anti-emetic, and anticancer properties. The study aimed to elucidate the apoptotic mechanisms of 6-gingerol in LNCaP human prostate cancer cells. Findings showed that 6-gingerol inhibits cell survival and persuades apoptosis in a dose- and time-dependent manner, mediated by the initiation of caspase-3 and subsequent cleavage of PARP. This suggests 6-gingerol as a potential chemopreventive agent for prostate cancer. However, further studies are needed to fully understand its mechanisms and evaluate its clinical efficacy and safety. J. Konmun et al. (2017)[9] conducted a randomized double-blind placebo-controlled study demonstrating that 6-gingerol, when used alongside standard anti-emetic medications (ondansetron, metoclopramide, and dexamethasone), significantly improves control of chemotherapy-induced nausea and vomiting (CINV). Its efficacy was particularly notable in the delayed phase of CINV and with repeated chemotherapy cycles, suggesting that chronic use may enhance effectiveness. Improvement in appetite and quality of life (QoL) supports 6-gingerol’s potential as a complementary therapy for CINV. The study reported high compliance and low incidence of severe adverse events, indicating that 6-gingerol is well-tolerated and safe for long-term use in chemotherapy patients. These findings warrant further investigation through a phase III randomized study to confirm the benefits and establish 6-gingerol’s role in clinical practice for CINV management. W. Marx et al. (2018)[10] conducted a randomized clinical trial highlighting the need for low-risk, cost-effective therapies to improve QoL, manage symptoms, and enhance survival rates for chemotherapy patients despite advancements in anticancer and anti-emetic treatments. Ginger has shown potential as an adjunct therapy for chemotherapy-induced nausea and vomiting in several clinical trials, prompting further investigation. This study aims to establish the safety of ginger supplementation, determine the optimal formulation and dosing, control potential confounders, and assess ginger’s effectiveness in alleviating CINV-related symptoms such as fatigue and compromised nutrition. Chi-Ming Liu et al. (2022)[11] conducted a randomized clinical trial demonstrating that 6-gingerol exhibits significant anticancer activities in prostate cancer cells. It inhibits cell viability, colony formation, migration, and invasion. The compound induces cell death through autophagy and ferroptosis by increasing ROS levels and modulating key autophagy-related proteins. 6-Gingerol’s ability to induce ferroptosis involves downregulating NRF2, leading to decreased GSH synthesis and GPX4 inhibition. These regulatory effects on oxidative stress pathways highlight 6-gingerol’s potential as a therapeutic agent against prostate cancer. The findings suggest that 6-gingerol could be a promising candidate for developing new treatments targeting prostate cancer, particularly in combating metastasis and drug resistance. Its multifaceted mechanisms, including the regulation of EMT and ferroptosis pathways, provide a strong rationale for further trial and clinical implications. This research underscores the potential of 6-gingerol in prostate cancer treatment, warranting further exploration in clinical settings. Megan Crichton et al. (2024)[12] conducted a randomized clinical trial suggesting that adjuvant ginger supplementation improves certain aspects of QoL for chemotherapy patients. Significant improvements were observed in nausea-related QoL, overall CINV-related QoL, delayed nausea and vomiting, and malnutrition. However, improvements in fatigue were limited to the first chemotherapy cycle, and ginger showed no significant effect on anticipatory or acute CINV, health-related QoL, anxiety, or depression. The clinical relevance of improvements in vomiting-related QoL and the number of delayed vomiting episodes was uncertain. The study indicates that while ginger can help manage some chemotherapy-induced symptoms, it may not address all areas of patient well-being during chemotherapy. These results highlight ginger’s potential as a complementary therapy in oncology, particularly for enhancing QoL by mitigating challenging chemotherapy side effects. Further research could refine the use of ginger and better understand its mechanisms to maximize its therapeutic benefits. Zohreh Salari et al. (2023)[13] reported that 6-gingerol, a natural compound from ginger, exhibits significant anticancer properties, such as inducing apoptosis and inhibiting angiogenesis. The study highlighted that combining 6-gingerol with cisplatin enhances anticancer efficacy and reduces side effects compared to using cisplatin alone. This combination therapy showed synergistic effects, supported by cytotoxicity, apoptosis, and gene expression data. The findings suggest that 6-gingerol could serve as a complementary therapy to cisplatin in ovarian cancer treatment, improving therapeutic outcomes and minimizing toxicity, making it a valuable addition to conventional cancer therapies. Baptista moreno martin AC et al. (2020)[14] reported that 6-gingerol, a natural compound derived from ginger, has significant anticancer properties, including inducing apoptosis and inhibiting angiogenesis. The study found that combining 6-gingerol with cisplatin enhances anticancer efficacy and reduces side effects compared to cisplatin alone. This combination showed synergistic effects, supported by cytotoxicity, apoptosis, and gene expression data. The findings suggest that 6-gingerol could be developed as a complementary therapy to cisplatin in treating ovarian cancer, offering improved therapeutic outcomes and reduced toxicity. Along with therapies such as radiotherapy, chemotherapy, and laser therapy, coconut oil (which has antibacterial effects) and natural substances such as gingerol can also be used for cancer cell death, which also helps in improving the QoL of the patients.[1718] CONCLUSION In conclusion, the systematic review of the modulatory effects of gingerol on cancer cell growth highlights its potential as a curative agent due to its ability to activate and suppress various signal pathways involved in cancer progression. Gingerol exhibits significant anticancer properties by inducing apoptosis, inhibiting proliferation, and preventing metastasis through the modulation of pathways. The review underscores the need for further in-depth testing to better understand the precise mechanisms and to validate the efficacy of gingerol in cancer treatment. Overall, gingerol shows promise as a complementary treatment in cancer therapy, offering a natural, multifaceted approach to targeting cancer cell growth. Conflicts of interest There are no conflicts of interest.